Web Results

Denosumab

en.wikipedia.org/wiki/Denosumab

Denosumab is a human monoclonal antibody for the treatment of osteoporosis, treatment-induced bone loss, metastases to bone, and giant cell tumor of bone.

For the Treatment of Postmenopausal Osteoporosis Women at High ...

www.prolia.com/

Learn how Prolia® (denosumab) can help in the treatment of postmenopausal osteoporosis for women at high risk for fracture.

FDA Approval for Denosumab - National Cancer Institute

www.cancer.gov/about-cancer/treatment/drugs/fda-denosumab

Jul 2, 2013 ... On June 13, 2013, the Food and Drug Administration (FDA) approved denosumab (Xgeva<sup>®</sup> injection, Amgen Inc., for subcutaneous use) for the ...

Denosumab (Prolia, Xgeva) | Cancer Research UK

www.cancerresearchuk.org/about-cancer/cancers-in-general/treatment/cancer-drugs/denosumab

Apr 23, 2015 ... Read about the cancer treatment drug denosumab, otherwise known as Prolia or Xgeva, including what it is, how it works and possible side ...

Denosumab for secondary bone cancer - Information and support ...

www.macmillan.org.uk/information-and-support/bone-cancer-secondary/treating/denosumab

Denosumab may be used to lower the risk of fractures caused by secondary bone cancers. It is also known as Xgeva<sup>®</sup> or Prolia<sup>®</sup>. It belongs to a group of cancer ...

XGEVA® vs Zoledronic Acid Study Design & Analysis | XGEVA® MOA

www.xgeva.com/hcp/overview/

Denosumab is an NCCN category 1–recommended treatment option for patients whose breast or prostate cancer has metastasized to bone1 1,2 ,2. Integrated

Prolia, Xgeva (denosumab) dosing, indications, interactions ...

reference.medscape.com/drug/prolia-denosumab-999566

Medscape - Osteoporosis, SREs, and giant cell tumor dosing for Prolia, Xgeva ( denosumab), frequency-based adverse effects, comprehensive interactions, ...

Role of RANK ligand and denosumab, a targeted RANK ligand ...

www.ncbi.nlm.nih.gov/pubmed/22440513

Clin Ther. 2012 Mar;34(3):521-36. doi: 10.1016/j.clinthera.2012.02.002. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health ...

Denosumab: a review of its use in postmenopausal women with ...

www.ncbi.nlm.nih.gov/pubmed/24935243

Drugs Aging. 2014 Jul;31(7):555-76. doi: 10.1007/s40266-014-0191-3. Denosumab: a review of its use in postmenopausal women with osteoporosis.

Denosumab, a fully human monoclonal antibody to RANKL, inhibits ...

www.ncbi.nlm.nih.gov/pubmed/19016581

Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/ human) ...

More Info

Denosumab Injection: MedlinePlus Drug Information

medlineplus.gov

Denosumab Injection: learn about side effects, dosage, special precautions, and more on MedlinePlus.

Denosumab: Indications, Side Effects, Warnings - Drugs.com

www.drugs.com

Easy to read patient leaflet for denosumab. Includes indications, proper use, special instructions, precautions, and possible side effects.

Dosing & Injection Administration | XGEVA® (denosumab) for HCPs

www.xgeva.com

<sup>*</sup>Bone complications, also known as skeletal-related events (SREs), are defined as radiation to bone, pathologic fracture, surgery to bone, and spinal cord ...